Skip to main content
COSMO Pharmaceuticals N.V. logo

COSMO Pharmaceuticals N.V. — Investor Relations & Filings

Ticker · COPN ISIN · NL0011832936 LEI · 724500OX0EBQRYTVV639 SW Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2023-09-04 Regulatory Filings
Country NL Netherlands
Listing SW COPN

About COSMO Pharmaceuticals N.V.

https://www.cosmopharma.com/

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.

Recent filings

Filing Released Lang Actions
Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
Regulatory Filings Classification · 95% confidence The document is a press release dated September 4, 2023, announcing a 'License and Supply Agreement' between Cosmo Pharmaceuticals N.V. and Adalvo Ltd. for a specific drug product. This type of announcement, detailing a significant business transaction (licensing, supply, partnership), does not fit neatly into the specific financial reporting categories like 10-K, ER, or IR. It is a material corporate event announcement. Since it is not a formal regulatory filing like a 10-K, nor a specific announcement like a dividend (DIV) or management change (MANG), the most appropriate general category for a significant, non-standard corporate announcement that is not a report itself is 'Regulatory Filings' (RNS), which serves as a broad category for material news releases that don't fit elsewhere, or potentially 'Capital/Financing Update' (CAP) if the focus was purely on funding, but here the focus is on a commercial agreement. Given the nature of a press release detailing a strategic business agreement, RNS is the best fit as a catch-all for material news not covered by other specific codes.
2023-09-04 English
Cosmo und Adalvo unterzeichnen Lizenz- und Liefervertrag für Rifamycin SV MMX® 200mg in den Regionen Europa, APAC, MENA und LATAM
Regulatory Filings Classification · 95% confidence The document is a press release dated September 4, 2023, announcing a licensing and supply agreement between Cosmo Pharmaceuticals N.V. and Adalvo Ltd. for a pharmaceutical product. This type of announcement, detailing a significant business transaction (licensing/partnership), does not fit neatly into the specific financial reporting categories like 10-K, ER, or IR. It is a general corporate announcement regarding business operations and strategy. Since it is not a standard regulatory filing form (like 10-K, DEF 14A, etc.) and is not a report itself (like an Audit Report or Interim Report), the most appropriate fallback category is 'Regulatory Filings' (RNS) for general corporate news releases that don't fit elsewhere, although 'Capital/Financing Update' (CAP) could be considered if the deal involved significant upfront capital, but the primary focus here is the licensing agreement itself. Given the options, RNS serves as the best general category for significant, non-standard corporate news releases.
2023-09-04 German
Cosmo presents strong H1 2023 operational and financial results
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and explicitly states it announces 'Cosmo presents strong H1 2023 operational and financial results'. It provides key financial figures for H1 2023 (Half Year 2023), including revenues, EBITDA, and operating profit, along with business highlights and an outlook. This content structure—a summary of period results released outside of the main annual or quarterly report filing—is characteristic of an Earnings Release (ER). Although it contains detailed figures, the context is an 'Ad hoc announcement' summarizing the period's performance, which aligns best with the ER definition (initial announcement of periodical financial results, key highlights only). It is not the comprehensive 'Interim / Quarterly Report' (IR) itself, as it is presented as a press release/ad hoc announcement, and it also mentions the full report is available for download, suggesting this is the initial release. The presence of a webcast invitation further supports this being an earnings announcement event. H1 2023
2023-07-26 English
Cosmo mit starken operativen und finanziellen Ergebnissen im 1. Halbjahr 2023
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and explicitly states it is 'Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR'. It presents key financial results for the '1. Halbjahr 2023' (First Half Year 2023), including revenue, EBITDA, and operational results, comparing them to H1 2022. This structure—a formal announcement detailing period-specific financial performance for a period shorter than a year (H1)—is characteristic of an Interim/Quarterly Report (IR). Although it is an announcement, the content is the core summary of the period's financials, making 'IR' a better fit than the general 'ER' (Earnings Release, usually quarterly highlights only) or 'RPA' (Report Publication Announcement, which usually just points to the full report). Since it covers a half-year period comprehensively, it aligns best with the Interim / Quarterly Report definition. H1 2023
2023-07-26 German
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
Report Publication Announcement Classification · 99% confidence The document is a press release dated July 5, 2023, announcing that Cosmo Pharmaceuticals N.V. will publish its 'Half-Year 2023 results' on July 26, 2023. It also invites participants to a live video webcast presentation to discuss these results. The key phrases are 'Half-Year 2023 results' and the announcement of a future event (the release and the webcast). Since this document is an announcement *about* the upcoming release of the Half-Year Report, and not the report itself, it fits the definition of a Report Publication Announcement (RPA). It is not the comprehensive Interim/Quarterly Report (IR) itself, but the notice of its publication and associated call. The document length (3813 chars) is short, supporting the RPA classification over the full report.
2023-07-05 English
Einladung zum Halbjahr 2023-Webcast von Cosmo am 26. Juli 2023
Report Publication Announcement Classification · 99% confidence The document is a press release dated July 5, 2023, announcing that the 'Halbjahresresultate 2023' (Half-Year Results 2023) will be published on July 26, 2023. It explicitly invites participants to a 'Live-Video-Webcast-Präsentation' to discuss the financial and operational results. Crucially, it states that the 'Medienmitteilung' (press release) and the 'Halbjahresbericht 2023' (Half-Year Report 2023) will be available for download on July 26th. Since this document is an announcement *about* the upcoming release of the half-year report and the associated webcast/call, and given its short length (under 5,000 characters), it fits the definition of a Report Publication Announcement (RPA). It is not the comprehensive Interim/Quarterly Report (IR) itself, nor is it the Earnings Release (ER) which typically contains the key figures immediately.
2023-07-05 German

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.